194 related articles for article (PubMed ID: 27998799)
1. Phospholipid complex enriched micelles: A novel drug delivery approach for promoting the antidiabetic effect of repaglinide.
Kassem AA; Abd El-Alim SH; Basha M; Salama A
Eur J Pharm Sci; 2017 Mar; 99():75-84. PubMed ID: 27998799
[TBL] [Abstract][Full Text] [Related]
2. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion.
Zawar LR; Bari SB
Chem Pharm Bull (Tokyo); 2012; 60(4):482-7. PubMed ID: 22466731
[TBL] [Abstract][Full Text] [Related]
4. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.
Yin LF; Huang SJ; Zhu CL; Zhang SH; Zhang Q; Chen XJ; Liu QW
Drug Dev Ind Pharm; 2012 Nov; 38(11):1371-80. PubMed ID: 22296267
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization and invivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles.
Dhana Lekshmi UM; Poovi G; Kishore N; Reddy PN
Int J Pharm; 2010 Aug; 396(1-2):194-203. PubMed ID: 20600729
[TBL] [Abstract][Full Text] [Related]
7. Hydrogels based on interpenetrating network of chitosan and polyvinyl pyrrolidone for pH-sensitive delivery of repaglinide.
Vaghani SS; Patel MM
Curr Drug Discov Technol; 2011 Jun; 8(2):126-35. PubMed ID: 21513486
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of solubility and antidiabetic effects of Repaglinide using spray drying technique in STZ-induced diabetic rats.
Varshosaz J; Minayian M; Ahmadi M; Ghassami E
Pharm Dev Technol; 2017 Sep; 22(6):754-763. PubMed ID: 26895041
[TBL] [Abstract][Full Text] [Related]
9. Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation.
Singh C; Bhatt TD; Gill MS; Suresh S
Int J Pharm; 2014 Jan; 460(1-2):220-7. PubMed ID: 24188983
[TBL] [Abstract][Full Text] [Related]
10. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
[TBL] [Abstract][Full Text] [Related]
11. A study on ethosomes as mode for transdermal delivery of an antidiabetic drug.
Bodade SS; Shaikh KS; Kamble MS; Chaudhari PD
Drug Deliv; 2013; 20(1):40-6. PubMed ID: 23311652
[TBL] [Abstract][Full Text] [Related]
12. Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method.
Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
Curr Drug Deliv; 2010 Jan; 7(1):44-50. PubMed ID: 20044909
[TBL] [Abstract][Full Text] [Related]
13. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2406-17. PubMed ID: 21491451
[TBL] [Abstract][Full Text] [Related]
14. Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo.
Yue PF; Yuan HL; Xie H; Xiao XH; Yang M; Liao MX; Zhu WF; Cai PL
Drug Dev Ind Pharm; 2008 Jul; 34(7):708-18. PubMed ID: 18612911
[TBL] [Abstract][Full Text] [Related]
15. Porous carrier based floating granular delivery system of repaglinide.
Jain SK; Agrawal GP; Jain NK
Drug Dev Ind Pharm; 2007 Apr; 33(4):381-91. PubMed ID: 17523003
[TBL] [Abstract][Full Text] [Related]
16. Poloxamer 407 microspheres for orotransmucosal drug delivery. Part I: formulation, manufacturing and characterization.
Albertini B; Passerini N; Di Sabatino M; Monti D; Burgalassi S; Chetoni P; Rodriguez L
Int J Pharm; 2010 Oct; 399(1-2):71-9. PubMed ID: 20696227
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a novel lipohydrogel nanocarrier: repaglinide as a lipophilic model drug.
Ebrahimi HA; Javadzadeh Y; Hamidi M; Barzegar Jalali M
J Pharm Pharmacol; 2016 Apr; 68(4):450-8. PubMed ID: 27114047
[TBL] [Abstract][Full Text] [Related]
18. Preparation of a nanoscale dihydromyricetin-phospholipid complex to improve the bioavailability: in vitro and in vivo evaluations.
Zhao X; Shi C; Zhou X; Lin T; Gong Y; Yin M; Fan L; Wang W; Fang J
Eur J Pharm Sci; 2019 Oct; 138():104994. PubMed ID: 31302210
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin.
Liu M; Cao W; Sun Y; He Z
Int J Pharm; 2014 Dec; 477(1-2):159-66. PubMed ID: 25455768
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization and tableting of cilnidipine solid dispersions.
Hu L; Song W; Niu F; Jiao K; Jia Z
Pak J Pharm Sci; 2013 May; 26(3):629-36. PubMed ID: 23625441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
